These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 12760865

  • 1. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT, Zurenko GE.
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
    [Abstract] [Full Text] [Related]

  • 2. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
    Munckhof WJ, Giles C, Turnidge JD.
    J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
    [Abstract] [Full Text] [Related]

  • 3. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
    Stefani S, Mezzatesta ML, Tempera G, Debbra E, Schito AM, Nicoletti G, Marchére A.
    Clin Microbiol Infect; 2002 Jun; 8(6):368-72. PubMed ID: 12084106
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [Abstract] [Full Text] [Related]

  • 5. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.
    Bell JM, Turnidge JD, Ballow CH, Jones RN, ZAPS Regional Participants.
    J Antimicrob Chemother; 2003 Feb; 51(2):339-45. PubMed ID: 12562700
    [Abstract] [Full Text] [Related]

  • 6. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE, Tenover FC.
    Microb Drug Resist; 2003 Feb; 9(4):389-93. PubMed ID: 15000746
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Steckelberg JM.
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [Abstract] [Full Text] [Related]

  • 8. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ.
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
    Johnson AP, Warner M, Livermore DM.
    J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
    [Abstract] [Full Text] [Related]

  • 10. In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals.
    Reis AO, Cordeiro JC, Machado AM, Sader HS.
    Braz J Infect Dis; 2001 Oct; 5(5):243-51. PubMed ID: 11779450
    [Abstract] [Full Text] [Related]

  • 11. [Surveillance for antimicrobial resistance: VIRA Study].
    Picazo JJ, Betriu C, Rodríguez-Avial I, Azahares E, Ali Sánchez B, Grupo VIRA.
    Enferm Infecc Microbiol Clin; 2002 Dec; 20(10):503-10. PubMed ID: 12433352
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
    Livermore DM, Warner M, Mushtaq S, North S, Woodford N.
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773
    [Abstract] [Full Text] [Related]

  • 13. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ, Chmelařová E.
    Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
    Jones RN, Fritsche TR, Sader HS, Ross JE.
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
    [Abstract] [Full Text] [Related]

  • 16. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.
    Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A.
    J Antimicrob Chemother; 2000 Dec; 46(6):931-40. PubMed ID: 11102412
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
    Ueda Y, Sunagawa M.
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
    [Abstract] [Full Text] [Related]

  • 18. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).
    Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN.
    Clin Microbiol Infect; 2002 Dec; 8(12):791-800. PubMed ID: 12519352
    [Abstract] [Full Text] [Related]

  • 19. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
    Yong D, Yum JH, Lee K, Chong Y, Choi SH, Rhee JK.
    Antimicrob Agents Chemother; 2004 Jan; 48(1):352-7. PubMed ID: 14693566
    [Abstract] [Full Text] [Related]

  • 20. Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium.
    Aligholi M, Emaneini M, Taherikalani M, Shahsavan S, Jabalameli F, Asadollahi P, Khoramian B, Eslampour MA.
    Acta Microbiol Immunol Hung; 2011 Sep; 58(3):219-26. PubMed ID: 21983323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.